Results 41 to 50 of about 8,627 (176)
New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
The review article study the safety and efficacy of using direct acting oral anticoagulants: thrombin inhibitor dabigatran etexilate and inhibitors Xa of the blood clotting factor apixaban, rivaroxaban and edoxaban compared with the vitamin K antagonist ...
E. I. Baranova
doaj +1 more source
Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol. [PDF]
Abstract Two Phase 1 open‐label studies were conducted in otherwise healthy participants, with BMI classified as overweight/obesity, to assess the potential of lotiglipron (a glucagon‐like peptide‐1 receptor agonist) as precipitant for pharmacokinetic (PK) drug–drug interactions (DDIs) when co‐administered with substrates of cytochrome P450 (CYP) 3A ...
Cronenberger C +11 more
europepmc +2 more sources
In this study, a dabigatran etexilate edisylate (DBE) was prepared by the reaction crystallization of dabigatran etexilate (DBG) and edisilic acid. According to single crystal X-ray diffraction (SXRD), it was revealed that two DGB were combined with one ...
Jin Feng +6 more
doaj +1 more source
The results of application of dabigatran etexilate in treatment of 56 patients aged 60 to 89 with closed diaphyseal fractures of femur and tibia undergone intramedullary osteosynthesis were studied. The patients were divided into 2 groups.
A. K. Dulaev, A. N. Tsed, I. G. Dzhusoev
doaj +1 more source
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation [PDF]
Objective To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant, versus warfarin and other alternatives for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation (AF).
Pan, Feng +6 more
core +1 more source
Introduction. Venous thromboembolism and atrial fibrillation are significant causes of vascular mortality. Anticoagulant therapy significantly reduces the risk of ischemic stroke, and dabigatran etexilate, a direct thrombin inhibitor, has become firmly ...
D. M. Devyatkina +5 more
doaj +1 more source
Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj +1 more source
Background: The most favorable gastrointestinal (GI) bleeding safety profile among different types of direct oral anticoagulants (DOACs) remains controversial. This meta-analysis includes the latest studies and aims to compare GI bleeding risk associated
Xiuehui Chen +5 more
doaj +1 more source
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed +7 more
wiley +1 more source
Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation [PDF]
Atrial fibrillation (AF) is associated with an increased risk of thromboembolism, and is the most prevalent factor for cardioembolic stroke. Vitamin K antagonists (VKAs) have been the standard of care for stroke prevention in patients with AF since the ...
Merkely, Béla Péter +21 more
core +2 more sources

